Nested case-control study: Hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 11, 2016, Pages 1197-1207

  Gounder, P P ^a   Bulkow, L R ^a   Snowball, M ^b   Negus, S ^b   Spradling, P R ^c   Simons, B C ^b   McMahon, B J ^a,b  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b ALASKA NATIVE TRIBAL HEALTH CONSORTIUM   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN;

ADOLESCENT; ADULT; AGE; ALASKA NATIVE; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHRONIC HEPATITIS B; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SURVEILLANCE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCLEARANCE; SEROLOGY; VIRAL CLEARANCE; AGED; CARCINOMA, HEPATOCELLULAR; CHILD; COMPLICATION; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY; INFANT; LIVER NEOPLASMS; MIDDLE AGED; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; RISK; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFANT; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; YOUNG ADULT;

EID: 84963811460     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13621     Document Type: Article

References (40)

1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ,. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546-55.
2. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS,. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34: 1329-39.
3. Ahn SH, Park YN, Park JY, et al,. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol 2005; 42: 188-94.
4. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC,. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13: 627-31.
5. Simonetti J, Bulkow L, McMahon BJ, et al,. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010; 51: 1531-7.
6. Bruix J, Sherman M,. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
7. Yang HI, Lu SN, Liaw YF, et al,. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
8. Yuen MF, Wong DK, Fung J, et al,. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008; 135: 1192-9.
9. Tong MJ, Nguyen MO, Tong LT, Blatt LM,. Development of hepatocellular carcinoma after seroclearance of hepatitis B surface antigen. Clin Gastroenterol Hepatol 2009; 7: 889-93.
10. Liu J, Yang HI, Lee MH, et al,. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma. Gut 2014; 63: 1648-57.
11. McMahon BJ,. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol Int 2009; 3: 334-42.
12. Chen CJ, Yang HI, Su J, et al,. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
13. McMahon BJ, Rhoades ER, Heyward WL, et al,. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives. Lancet 1987; 2: 1134-6.
14. McMahon BJ, Bulkow L, Harpster A, et al,. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000; 32: 842-6.
15. McMahon BJ, Holck P, Bulkow L, Snowball M,. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-68.
16. State of Alaska. Alaska population overview: 2013 estimates. Alaska Department of Labor and Workforce Development, Juneau, AK2014.
17. Parkinson AJ, Hennessy T, Bulkow L, Smith HS,. The Alaska Area Specimen Bank: a tribal-federal partnership to maintain and manage a resource for health research. International Journal of Circumpolar Health 2013; 72: 20607.
18. Fu SC, Huang YW, Wang TC, Hu JT, Chen DS, Yang SS,. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with new onset diabetes: a nationwide cohort study. Aliment Pharmacol Ther 2015; 41: 1200-9.
19. Loomba R, Liu J, Yang HI, et al,. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. Clin Gastroenterol Hepatol 2013; 11: 1636-45.e1-3.
20. Yasui K, Hashimoto E, Komorizono Y, et al,. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9: 428-33; quiz e50.
21. Lewis S, Roayaie S, Ward SC, Shyknevsky I, Jibara G, Taouli B,. Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis. Am J Roentgenol 2013; 200: W610-6.
22. Livingston SE, Simonetti JP, Bulkow LR, et al,. Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology 2007; 133: 1452-7.
23. About the SEER registries: National Cancer Institute Surveillance Research Program. Available at: http://seer.cancer.gov/registries/ (accessed July 15 #bib2015).
24. Wai CT, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
25. Vallet-Pichard A, Mallet V, Nalpas B, et al,. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.
26. Arase Y, Ikeda K, Suzuki F, et al,. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med 2006; 119: 71 e9-16.
27. Ringelhan M, O'Connor T, Protzer U, Heikenwalder M,. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol 2015; 235: 355-67.
28. Wong GLH, Tse YK, Chan HLY, Yip TCF, Tsoi KKF, Wong VWS,. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2016; 43: 802-813.
29. Coffin CS, Rezaeeaval M, Pang JX, et al,. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther 2014; 40: 1262-9.
30. Singal AK, Salameh H, Kuo YF, Fontana RJ,. Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38: 98-106.
31. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL,. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-77.
32. Chemin I, Zoulim F,. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009; 286: 52-9.
33. McMahon BJ, Bulkow L, Simons B, et al,. Relationship between level of hepatitis B virus DNA and liver disease: a population-based study of hepatitis B e antigen-negative persons with hepatitis B. Clin Gastroenterol Hepatol 2014; 12: 701-6.e3.
34. Tohme RA, Bulkow L, Homan CE, Negus S, McMahon BJ,. Rates and risk factors for hepatitis B reactivation in a cohort of persons in the inactive phase of chronic hepatitis B-Alaska, 2001-2010. J Clin Virol 2013; 58: 396-400.
35. McMahon BJ,. Natural history of chronic hepatitis B. Clin Liver Dis 2010; 14: 381-96.
36. Liu CJ, Chen PJ, Lai MY, et al,. A prospective study characterizing full-length hepatitis B virus genomes during acute exacerbation. Gastroenterology 2003; 124: 80-90.
37. Beasley RP, Hwang LY, Lin CC, Chien CS,. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 1129-33.
38. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP,. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150: 1051-4.
39. McMahon BJ, Alward WL, Hall DB, et al,. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599-603.
40. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.